MarketCapExport financials
IDEAYA Biosciences (IDYA)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
IDEAYA Biosciences Cash Flow 2025-2011 | IDYA
Brief overview of IDEAYA Biosciences's cash generation
Cash flows are assessed across five available annual periods spanning 2021 to 2025.
Operating cash flow ended negative at -$71.1 million. Core operations are not yet producing a sustainable inflow.
Operating cash flow was positive in only 0 of five periods. Cash generation remains unstable.
Overall picture
IDEAYA Biosciences has limited cash flow resilience; a return to stable positive cash generation is the main condition for improvement.
Annual Cash Flow IDEAYA Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
-71.1 M | -248 M | -115 M | -87.2 M | -55.8 M | 55.5 M | -39.3 M | -27.6 M | -12.2 M | - | - | - | - | - | - |
Depreciation & Amortization |
2.7 M | 2.39 M | 2.48 M | 2.1 M | 1.72 M | 1.38 M | 1.24 M | 886 K | 391 K | - | - | - | - | - | - |
Accounts Payables |
17.6 M | 15.4 M | 6.6 M | 4.28 M | 2.1 M | 953 K | 709 K | - | - | - | - | - | - | - | - |
Accounts Receivables |
- | 3 K | 18 K | 211 K | 1.1 M | 1.88 M | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Cash Flow IDEAYA Biosciences
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
-163 M | -75.2 M | - | - | - | -60.3 M | - | - | - | -43.8 M | - | - | - | -27.8 M | - | -63.8 M | -39.6 M | -19.6 M | - | -39.1 M | -26.7 M | -13.7 M | - | 67.1 M | -23.2 M | -9.54 M | - | -30.6 M | -20.1 M | -9.78 M | - | -20.1 M | -11.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Depreciation & Amortization |
1.38 M | 688 K | - | 700 K | 700 K | 600 K | - | 600 K | 600 K | 616 K | - | 600 K | 600 K | 588 K | - | 600 K | 500 K | 464 K | - | 1.28 M | 826 K | 382 K | - | 1.02 M | 673 K | 336 K | - | 915 K | 591 K | 293 K | - | 623 K | 400 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Accounts Payables |
30.5 M | 20.7 M | 17.6 M | 18.4 M | 17.3 M | 17.6 M | 15.4 M | 12.6 M | 15.9 M | 6.29 M | 6.6 M | 5.17 M | 5.87 M | 4.38 M | 4.28 M | 3.64 M | 4.23 M | 3.36 M | 2.1 M | 2.15 M | 2.11 M | 1.28 M | 953 K | 953 K | 953 K | 953 K | 709 K | 709 K | 709 K | 709 K | 1.42 M | 1.42 M | 1.42 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Accounts Receivables |
- | - | - | - | - | - | - | 20 K | 1 K | 15 K | 18 K | 6.7 M | 160 K | 468 K | 211 K | 3.45 M | 288 K | 697 K | 1.1 M | 1.02 M | 1.32 M | 2.92 M | 1.88 M | 1.88 M | 1.88 M | 1.88 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Cash Flow Statement is one of the three key financial reports of the company IDEAYA Biosciences, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Biotechnology sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Bicycle Therapeutics plc
BCYC
|
$ 3.46 | 2.56 % | $ 240 M |  Britain |
 |
Beam Therapeutics
BEAM
|
$ 23.47 | 4.57 % | $ 2.32 B |  USA |
 |
Benitec Biopharma
BNTC
|
$ 8.11 | 2.05 % | $ 378 M | USA |
 |
BioNTech SE
BNTX
|
$ 87.71 | 1.74 % | $ 21.2 B |  Germany |
 |
ANI Pharmaceuticals
ANIP
|
$ 72.29 | 0.01 % | $ 1.45 B | USA |
 |
C4 Therapeutics
CCCC
|
$ 2.77 | 0.36 % | $ 230 M | USA |
 |
Cerus Corporation
CERS
|
$ 2.18 | 0.66 % | $ 415 M | USA |
 |
Certara
CERT
|
$ 9.37 | 0.26 % | $ 1.5 B | USA |
 |
Coherus BioSciences
CHRS
|
$ 0.99 | 1.9 % | $ 116 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
$ 110.16 | 0.47 % | $ 11.4 B | USA |
 |
CorMedix
CRMD
|
$ 7.26 | 0.95 % | $ 523 K | USA |
 |
CRISPR Therapeutics AG
CRSP
|
$ 49.25 | 2.59 % | $ 4.43 B |  Schweiz |
 |
Greenwich LifeSciences
GLSI
|
$ 14.55 | 1.48 % | $ 197 M | USA |
 |
Champions Oncology
CSBR
|
$ 4.7 | 0.94 % | $ 65 M | USA |
 |
Cue Biopharma
CUE
|
$ 16.71 | 0.38 % | $ 1.58 B | USA |
 |
DBV Technologies S.A.
DBVT
|
$ 9.05 | 2.71 % | $ 1.26 B |  France |
 |
Alterity Therapeutics Limited
ATHE
|
$ 2.62 | 8.64 % | $ 16.8 B |  Australia |
 |
Actinium Pharmaceuticals
ATNM
|
$ 1.13 | 6.6 % | $ 35.3 M | USA |
 |
DiaMedica Therapeutics
DMAC
|
$ 7.57 | 0.75 % | $ 356 M | USA |
 |
Aytu BioScience
AYTU
|
$ 1.98 | 1.0 % | $ 24.4 M | USA |
 |
Dyadic International
DYAI
|
$ 0.41 | 1.55 % | $ 14.8 M | USA |
 |
Edesa Biotech
EDSA
|
$ 2.57 | 0.37 % | $ 14.6 M | USA |
 |
Lantern Pharma
LTRN
|
$ 0.67 | 0.24 % | $ 7.3 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
$ 9.98 | 3.71 % | $ 285 M | USA |
 |
Cardiff Oncology
CRDF
|
$ 0.9 | 0.7 % | $ 60.2 M | USA |
 |
Inhibrx
INBX
|
$ 89.83 | 6.15 % | $ 4.23 B | USA |
 |
Eton Pharmaceuticals
ETON
|
$ 50.31 | 0.3 % | $ 1.35 B | USA |
 |
ImmuCell Corporation
ICCC
|
$ 10.75 | 1.8 % | $ 97 M | USA |
 |
Fulcrum Therapeutics
FULC
|
$ 3.65 | 0.14 % | $ 231 M | USA |
 |
Kamada Ltd.
KMDA
|
$ 7.76 | 0.04 % | $ 447 M |  Israel |
 |
InflaRx N.V.
IFRX
|
$ 1.32 | 1.69 % | $ 88.8 M | Germany |
 |
Immutep Limited
IMMP
|
$ 3.18 | 0.93 % | $ 4.63 B | Australia |
 |
Mustang Bio
MBIO
|
$ 0.38 | 3.6 % | $ 1.87 M | USA |
 |
Kala Pharmaceuticals
KALA
|
$ 0.19 | 0.57 % | $ 1.55 M | USA |
 |
Mereo BioPharma Group plc
MREO
|
$ 0.3 | 1.32 % | $ 239 M | Britain |
 |
Kiniksa Pharmaceuticals, Ltd.
KNSA
|
$ 78.59 | 1.4 % | $ 5.83 B | USA |
 |
Karyopharm Therapeutics
KPTI
|
$ 0.39 | 11.2 % | $ 4.26 K | USA |
 |
Seres Therapeutics
MCRB
|
$ 2.46 | 1.19 % | $ 21.8 M | USA |